AU2019403396B2 - Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof - Google Patents

Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof Download PDF

Info

Publication number
AU2019403396B2
AU2019403396B2 AU2019403396A AU2019403396A AU2019403396B2 AU 2019403396 B2 AU2019403396 B2 AU 2019403396B2 AU 2019403396 A AU2019403396 A AU 2019403396A AU 2019403396 A AU2019403396 A AU 2019403396A AU 2019403396 B2 AU2019403396 B2 AU 2019403396B2
Authority
AU
Australia
Prior art keywords
cancer
compound
pharmaceutical composition
tris
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019403396A
Other languages
English (en)
Other versions
AU2019403396A1 (en
Inventor
Syed Altaf
Abira RAMAKRISHNAN
Jacob SIZEMORE
Shijie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2019403396A1 publication Critical patent/AU2019403396A1/en
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER Amend patent request/document other than specification (104) Assignors: LES LABORATOIRES SERVIER SAS
Application granted granted Critical
Publication of AU2019403396B2 publication Critical patent/AU2019403396B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019403396A 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof Active AU2019403396B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US62/784,083 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US62/791,571 2019-01-11
US201962882712P 2019-08-05 2019-08-05
US62/882,712 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
AU2019403396A1 AU2019403396A1 (en) 2021-07-08
AU2019403396B2 true AU2019403396B2 (en) 2024-12-12

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019403396A Active AU2019403396B2 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Country Status (23)

Country Link
US (2) US12297179B2 (enExample)
EP (1) EP3898597A1 (enExample)
JP (3) JP2022515239A (enExample)
KR (1) KR20220035022A (enExample)
CN (1) CN113508108B (enExample)
AU (1) AU2019403396B2 (enExample)
BR (1) BR112021012305A2 (enExample)
CA (1) CA3124401A1 (enExample)
CL (1) CL2021001640A1 (enExample)
CO (1) CO2021009309A2 (enExample)
CR (1) CR20210394A (enExample)
GE (2) GEAP202415700A (enExample)
IL (1) IL284218B1 (enExample)
JO (1) JOP20210147A1 (enExample)
MA (1) MA54541A (enExample)
MX (1) MX2021007536A (enExample)
NI (1) NI202100055A (enExample)
PE (2) PE20212197A1 (enExample)
PH (1) PH12021551495A1 (enExample)
SG (1) SG11202106526UA (enExample)
TW (1) TWI875727B (enExample)
UA (1) UA130491C2 (enExample)
WO (1) WO2020132471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128669A2 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9012464B2 (en) * 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
TWI818954B (zh) * 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
CA3184024A1 (en) * 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014128669A2 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2018197997A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Also Published As

Publication number Publication date
NI202100055A (es) 2021-12-01
MX2021007536A (es) 2021-09-23
BR112021012305A2 (pt) 2021-10-05
GEAP202415700A (en) 2024-05-13
JP7749080B2 (ja) 2025-10-03
TWI875727B (zh) 2025-03-11
CA3124401A1 (en) 2020-06-25
CN113508108B (zh) 2024-12-24
AU2019403396A1 (en) 2021-07-08
CL2021001640A1 (es) 2022-06-03
CN113508108A (zh) 2021-10-15
JOP20210147A1 (ar) 2023-01-30
KR20220035022A (ko) 2022-03-21
US12297179B2 (en) 2025-05-13
IL284218A (en) 2021-08-31
WO2020132471A1 (en) 2020-06-25
US20250270175A1 (en) 2025-08-28
PH12021551495A1 (en) 2022-03-07
JP2026001058A (ja) 2026-01-06
SG11202106526UA (en) 2021-07-29
UA130491C2 (uk) 2026-03-04
CO2021009309A2 (es) 2021-10-29
WO2020132471A8 (en) 2020-08-06
PE20212197A1 (es) 2021-11-16
PE20260309A1 (es) 2026-02-11
GEP20247683B (en) 2024-10-28
EP3898597A1 (en) 2021-10-27
MA54541A (fr) 2022-03-09
JP2024161431A (ja) 2024-11-19
US20220055995A1 (en) 2022-02-24
TW202039448A (zh) 2020-11-01
JP2022515239A (ja) 2022-02-17
IL284218B1 (en) 2026-01-01
CR20210394A (es) 2021-12-13

Similar Documents

Publication Publication Date Title
US20250270175A1 (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
EP3702351B1 (en) Formulation comprising a mek inhibitor
US11951100B2 (en) Formulations of RBP4 inhibitors and methods of use
EP1709053B1 (en) Stable salts of olanzapine
EP2582689A1 (en) New polymorphic form of imatinib base and preparation of salts thereof
CN113968843A (zh) 一种环己烷甲酰胺的新晶型及其制备方法
KR102903080B1 (ko) 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
WO2018073574A1 (en) Polymorphic forms of palbociclib
OA20637A (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof.
EA045339B1 (ru) Кристаллические и солевые формы органического соединения и их фармацевтические композиции
WO2011027988A2 (en) Novel polymorphic form of prasugrel-hydrogen sulfate
AU2020378025A1 (en) Crystal form of Aprocitentan, preparation method therefor and use thereof
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
US10793554B2 (en) Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
KR101872726B1 (ko) 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: LES LABORATOIRES SERVIER

Free format text: FORMER NAME(S): LES LABORATOIRES SERVIER SAS

FGA Letters patent sealed or granted (standard patent)